# Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

> **NCT07560488** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 43 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma
- Conversion Therapy

## Interventions

- **DRUG:** Bevacizumab Biosimilar IBI305
- **DRUG:** ipilimumab N01
- **DRUG:** Sintilimab
- **DRUG:** HAIC

## Key facts

- **NCT ID:** NCT07560488
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2027-04
- **Final completion:** 2028-04
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07560488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07560488, "Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07560488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*